As one of many businesses, the PBLA published as well the fourth quarter of 2022 effort

The stockholders did not anticipate any modifications at the business during the the October to December 31 2022 reporting cycle at the company. But, investors monitor PBLAs' operating deficit which was at $-5.18 millions, during the matching time.

The operating deficit has depleted from $-3.326 millions, from the fourth quarter of 2021. But more crucially, the investors are speculating, if the Major Pharmaceutical Preparations company's will begin to report the revenue.


The CFO is on the quest for distinct financial plans, consecutively to obtain constant service. Over the same period the deficit, which the company has dealt with during the arising cycle, has extended to $-4.735 millions, from $-3.550 millions, from the comparable reporting period a year ago.

Panbela Therapeutics Inc announced loss of $-34.93 millions and Revenues of $0.00 millions in the fiscal year 2022.

Net loss per share has widen to $-67.91 from $-0.87 in prior fiscal year, while by 0 % from $0.00 millions a year prior.

Panbela Therapeutics Inc is expected to report next financial earnings on May 11, 2023.

Panbela Therapeutics Inc's Receivables Turnover Ratio

Panbela Therapeutics Inc's Receivables Turnover Ratio

Other PBLA's Earnings Reports

PBLA, reduction in the corporate performance all over financial interval ending third quarter of 2022

PBLA, deterioration in the company conduct all over financial second quarter of 2022

Business expenses were growing at the company in the first quarter of 2022 earnings season